QLGN News and Press, Qualigen Therapeutics Inc. From 11/13/20

Qualigen Therapeutics (QLGN): FQ2 GAAP EPS of -$0.41 misses by $0.61.Revenue of $0.84M (-30.0% Y/Y) misses by $0.75M.Press Release For further details see: Qualigen Therapeutics EPS misses by $0.61, misses on revenue

Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results PR Newswire CARLSBAD, Calif., Nov. 13, 2020 CARLSBAD, Calif. , Nov. 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (...

Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials PR Newswire CARLSBAD, Calif., Nov. 5, 2020 CARLSBAD, Calif. , Nov. 5, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has...

Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19 Plans to File IND Application and Initiate Phase 2a Study in First Half of 2021 PR Newswire CARLSBAD, Calif., Oct. 28, 2020 CARL...

Qualigen Therapeutics ([[QLGN]] +3.6%) has entered an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of diagnostic test systems based on Qualigen's core FastPack "laboratory in a pouch" technology.Qualigen granted Yi Xin e...

Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China Yi Xin Zhen Duan Jishu will develop new generations of FastPack-based diagnostic systems while manufacturing and selling current products PR Newswire CARLSBA...

Qualigen Therapeutics ([[QLGN]] -3.4%) has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of its AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin) for the treatment of pediatric and adult acute myeloid leukemia...

Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate In addition to acute myeloid leukemia, preclinical studies will focus on glioblastoma and lung cancer, and the use of ALAN as a potential adjuvant therapy PR Newswir...

Qualigen Therapeutics ( QLGN )  jointly files U.S. provisional patent application with the University of Louisville, entitled "Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent." More news on: Qualigen Therapeutics, Inc., Heal...

CARLSBAD, Calif. , Sept. 17, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces its and the University of Louisville's joint filing of a United States provisional patent application, entitled "Methods of inhibiting or treating coronavirus infection, and method...